GEN Exclusives

More »

GEN News Highlights

More »
Jun 2, 2009

Abbott and BioGenex Continue Partnership to Automate FISH Assay Workflow

  • Abbott has extended an agreement to market BioGenex’ Xmatrx® platform for the automation of its FISH product line. Under the terms of the agreement, BioGenex will receive a multiyear minimum volume commitment from Abbott.

    The original technology co-development and distribution agreement and this extension give Abbott customers will have the option to run IHC and FISH on the Xmatrx, and BioGenex customers to run FISH on their system. The Xmatrx will be co-branded and marketed, and both parties to collaborate in aiding adoption of FISH, IHC, and ISH as primary tools in molecular diagnostics and personalized medicine.

    The Xmatrx platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pre-treatment to final cover-slipping, according to BioGenex. It is designed for optimal results with Abbott Molecular AutoFISH™ reagents and FISH technology.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »